Based on the key indicators related to Rocket Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Rocket Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Rocket Pharmaceuticals' Short Term Debt is comparatively stable compared to the past year. Common Stock is likely to gain to about 1.1 M in 2025, whereas Total Stockholder Equity is likely to drop slightly above 255 M in 2025. Key indicators impacting Rocket Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Rocket Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Rocket Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Rocket Pharmaceuticals.
Please note, the imprecision that can be found in Rocket Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Rocket Pharmaceuticals. Check Rocket Pharmaceuticals' Beneish M Score to see the likelihood of Rocket Pharmaceuticals' management manipulating its earnings.
Rocket Pharmaceuticals Stock Summary
Rocket Pharmaceuticals competes with Uniqure NV, Rhythm Pharmaceuticals, Solid Biosciences, MeiraGTx Holdings, and Vaxcyte. Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey. Rocket Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Rocket Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Rocket Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Rocket Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Rocket Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rocket Pharmaceuticals competition to find correlations between indicators driving Rocket Pharmaceuticals's intrinsic value. More Info.
Rocket Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Rocket Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Rocket Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Rocket Pharmaceuticals Systematic Risk
Rocket Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Rocket Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Rocket Pharmaceuticals correlated with the market. If Beta is less than 0 Rocket Pharmaceuticals generally moves in the opposite direction as compared to the market. If Rocket Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Rocket Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Rocket Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Rocket Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Rocket Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Rocket Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Rocket Pharmaceuticals growth as a starting point in their analysis.
Rocket Pharmaceuticals March 24, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Rocket Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Rocket Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Rocket Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Rocket Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Rocket Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Rocket Pharmaceuticals' price analysis, check to measure Rocket Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rocket Pharmaceuticals is operating at the current time. Most of Rocket Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rocket Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rocket Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rocket Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.